^
Association details:
| Biomarker: | CD36 overexpression + CD47 overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | VT1021 (CD36 stimulant, TSP1 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors
Published date:
11/09/2020
Excerpt:
...VT1021 has demonstrated activities in reprogramming the TME which resulted in a high disease control rate in subjects with tumors expressing both high CD36 and high CD47.
DOI:
10.1136/jitc-2020-SITC2020.0374
Trial ID:
